Medtronic has announced that the US FDA has cleared an expanded indication for the OsteoCool radiofrequency (RF) ablation system.
The Karolinska Institute-sponsored, prospective, observational MAVERRIC study aims to demonstrate that a strategy of first line local microwave ablation of colorectal liver metastases is not inferior to liver resection in terms of survival rates at three years.
Sirtex has announced that the SARAH (Sorafenib vs. radioembolisation in advanced hepatocellular carcinoma) randomised controlled study results will be presented at the upcoming European Association for the Study of the Liver (EASL), International Liver Congress (ILC) in Amsterdam, the Netherlands (19–23 April 2017).
WCIO has announced via email communication that the board of directors of the organisation, a non-profit association that supports and promotes the field of interventional oncology (IO), has established the Society of Interventional Oncology (SIO), effective 17 January. The society’s annual IO conference will maintain its name of WCIO.
A study, published in the Journal of Vascular and Interventional Radiology suggests that percutaneous image-guided irreversible electroporation of unresectable locally advanced pancreatic adenocarcinoma is associated with a satisfactory safety profile.
Guerbet has announced that the Thailand FDA has given approval of a new indication for Lipiodol Ultra-Fluide for selective hepatic intra-arterial injection for visualisation, localisation and vectorisation during transarterial chemoembolization of tumours in adults with known, intermediate stage hepatocellular carcinoma.
Daniel Sze, speaking at the ninth annual Symposium on Clinical Interventional Oncology (CIO; 4–5 February 2017, Hollywood, USA), noted that immunotherapy is a “huge opportunity” for interventional oncology.
A minimally invasive treatment for migraine headaches used for adults is also proving to be a safe and effective treatment for children and teenagers. Further, it only takes minutes for a child to feel relief, according to new research being presented today at the Society of Interventional Radiology’s 2017 annual scientific meeting (4–9 March, Washington, DC, USA).
A large US nationwide study shows that the uterine fibroid embolization is vastly underutilised, compared to hysterectomy—especially in rural and smaller hospitals.
Data from the randomised controlled ATTRACT trial revealed that the addition of catheter-based intervention to standard-of-care anticoagulation failed to significantly decrease the occurrence of post-thrombotic syndrome in patients who received this treatment strategy when compared to its occurence in patients who received anticoagulation alone. While there is disappointment at the headline findings of this landmark trial, experts have called the data both illuminating and hypothesis-generating.
Bluegrass Vascular has announced that it is entering into a strategic relationship with Merit Medical. The agreement will streamline European distribution of the recently CE mark approved Surfacer inside-out access catheter system and will provide funding to support the company’s efforts to secure FDA clearance for product sales in the USA.
BTG has received Class III CE mark certification for DC Bead Lumi, the first commercially available radiopaque drug-eluting bead (DEB) in the EU which can be loaded with doxorubicin or irinotecan for the local treatment of tumours in patients with hepatocellular carcinoma and malignant colorectal cancer metastasised to the liver. According to a company release, for the first time, DC Bead Lumi provides real-time visible and lasting confirmation of bead location.
Medtronic has been granted CE mark approval for the HawkOne directional atherectomy system in a lower profile size for treating patients with peripheral artery disease. The new HawkOne 6 Fr provides an effective and easy-to-use treatment option for patients with peripheral artery disease both above and below the knee with a single device. The HawkOne system is designed to remove plaque from the vessel wall and restore blood flow.
The final 12-month results of the Stellarex (Spectranetics) drug-coated balloon ILLUMENATE Global Study have found high primary patency and freedom from clinically driven target lesion revascularisation results.
Interim data presented at the 2017 Leipzig Interventional Course (LINC; 24-27 January, Leipzig, Germany) has demonstrated encouraging results for Biotronik’s dedicated lower limb intervention portfolio.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos